{"id":750169,"date":"2023-04-24T07:04:27","date_gmt":"2023-04-24T11:04:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/"},"modified":"2023-04-24T07:04:27","modified_gmt":"2023-04-24T11:04:27","slug":"bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/","title":{"rendered":"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023"},"content":{"rendered":"
\n

NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company\u2019s financial results and to provide a general business update.<\/p>\n\n\n\n\n\n\n
\n Conference Call & Webcast Details<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Date\/Time:<\/strong>
\n \n <\/td>\n		Monday, May 8, 2023 at 8:00 AM Eastern Time<\/td>\n<\/tr>\n
\n Domestic:<\/strong>\n <\/td>\n877-407-5795<\/td>\n<\/tr>\n
\n International:<\/strong>
\n \n <\/td>\n		201-689-8722<\/td>\n<\/tr>\n<\/table>\n

The webcast and the accompanying materials will be accessible* under “News\/Events” on the Investors & Media page of the Company’s website at\u00a0www.bioxceltherapeutics.com<\/a>.<\/p>\n\n\n\n\n\n\n
\n Replay<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n Domestic:<\/strong>
\n \n <\/td>\n		877-660-6853<\/td>\n<\/tr>\n
\n International:<\/strong>\n <\/td>\n201-612-7415<\/td>\n<\/tr>\n
\n Conference ID:<\/strong>\n <\/td>\n13738246<\/td>\n<\/tr>\n<\/table>\n

*Replay available through August 8, 2023<\/p>\n

\n About BioXcel Therapeutics, Inc.<\/strong>
\n
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company\u2019s drug re-innovation approach leverages existing approved drugs and\/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. The Company\u2019s commercial product, IGALMI\u2122 (developed as BXCL501), is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose. For more information, please visit\u00a0IGALMIhcp.com<\/a>\u00a0and also see the IGALMI full\u00a0Prescribing Information<\/a>.\u00a0BXCL501 is under evaluation for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for acute treatment of Alzheimer\u2019s-related agitation, and as an adjunctive treatment for major depressive disorder. The safety and efficacy of BXCL501 for these uses have not been established. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics LLC, the Company is developing BXCL701, an investigational, oral innate immune activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment na\u00efve to checkpoint inhibitors. The safety and efficacy of BXCL502 and BXCL701 have not been established. For more information, please visit\u00a0bioxceltherapeutics.com<\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>
\n
This press release includes \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, the date and time of the Company\u2019s first quarter 2023 financial results call. When used herein, words including \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesigned,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company\u2019s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption \u201cRisk Factors\u201d in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC\u2019s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company\u2019s views as of any date subsequent to the date of this press release.<\/p>\n

Contact Information<\/p>\n

\n Corporate<\/u>\n <\/p>\n

BioXcel Therapeutics
Erik Kopp
1.203.494.7062
ekopp@bioxceltherapeutics.com<\/a><\/p>\n

\n Investor Relations<\/u>\n <\/p>\n

BioXcel Therapeutics
Brennan Doyle
1.475.355.8462
bdoyle@bioxceltherapeutics.com<\/a><\/p>\n

\n Media<\/u>\n <\/p>\n

Russo Partners
David Schull or Scott Stachowiak
1.858.717.2310
David.schull@russopartnersllc.com<\/a>
Scott.stachowiak@russopartnersllc.com<\/a><\/p>\n

Source: BioXcel Therapeutics, Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company\u2019s financial results and to provide a general business update. Conference Call & Webcast Details \u00a0 \u00a0 Date\/Time: Monday, May 8, 2023 at 8:00 AM Eastern Time Domestic: 877-407-5795 International: 201-689-8722 The webcast and the accompanying materials will be accessible* under “News\/Events” on the Investors … <\/p>\n

Continue reading “BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750169","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company\u2019s financial results and to provide a general business update. Conference Call & Webcast Details \u00a0 \u00a0 Date\/Time: Monday, May 8, 2023 at 8:00 AM Eastern Time Domestic: 877-407-5795 International: 201-689-8722 The webcast and the accompanying materials will be accessible* under “News\/Events” on the Investors … Continue reading "BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-24T11:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023\",\"datePublished\":\"2023-04-24T11:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/\"},\"wordCount\":815,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/\",\"name\":\"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=\",\"datePublished\":\"2023-04-24T11:04:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/","og_locale":"en_US","og_type":"article","og_title":"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023 - Market Newsdesk","og_description":"NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company\u2019s financial results and to provide a general business update. Conference Call & Webcast Details \u00a0 \u00a0 Date\/Time: Monday, May 8, 2023 at 8:00 AM Eastern Time Domestic: 877-407-5795 International: 201-689-8722 The webcast and the accompanying materials will be accessible* under “News\/Events” on the Investors … Continue reading \"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-24T11:04:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023","datePublished":"2023-04-24T11:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/"},"wordCount":815,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/","name":"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=","datePublished":"2023-04-24T11:04:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzAxMiM1NTQwMjQ0IzIxOTI5NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750169"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}